This blog post is supporting my poster at Young Modellers Forum and makes things way easier to see and understand. Underneath each GIF, is the explanation of what you should look for as things denoise throughout the diffusion trajectory. Click the GIFs for higher quality viewing!
Continue readingCategory Archives: Small Molecules
Design your very own drug: An introduction to structure-based small molecule drug design
Are you curious about how scientists design small molecules to treat disease using computational tools, but the words RDKit, docking, and QED mean nothing to you? Look no further than these tutorials for learning the fundamentals of computational small molecule drug design through interactive tutorials that introduce the key tools, concepts, and workflows. From generating compounds to evaluating their drug-likeness and binding potential, by the end you’ll be ready to explore how computational methods can result in the discovery of your very own (virtual) drug candidates to cure Zika!
Find the materials here: https://github.com/oxpig/dtc-struc-bio-smolecules/tree/main.
Continue readingIs the molecule in the computer?
The Molecular Graphics and Modelling Society began life as the Molecular Graphics Society. It’s hard to imagine a time without computer graphics, but yes, it existed. The MGS was formed by the pioneers who made molecular graphics commonplace.
In 1994, the MGS organized an Art and Video Show (Goodsell et al., 1995), and I submitted some of my own work. One of the other images — inspired by Magritte‘s “Ceci n’est pas une pipe”, depicts a molecule with a remarkable similarity to a pipe — and to a molecule… It was submitted by Mike Hann (of GSK):
Fragment-to-Lead Successes in 2023
Back in 2021, I highlighted the annual fragment-to-lead (F2L) success stories from 2019 [Blog post] [Paper]. This is one of my favourite annual publications, and I’m delighted to see that it’s still going strong. In this post, I’ll discuss the 2023 edition that was published in at the start of 2025 [Paper].
Extracting 3D Pharmacophore Points with RDKit
Pharmacophores are simplified representations of the key interactions ligands make with proteins, such as hydrogen bonds, charge interactions, and aromatic contacts. Think of them as the essential “bumps and grooves” on a key that allow it to fit its lock (the protein). These maps can be derived from ligands or protein–ligand complexes and are powerful tools for virtual screening and generative models. Here, we’ll see how to extract 3D pharmacophore points from a ligand using RDKit.
(Code adapted from Dr. Ruben Sanchez.)
Why pharmacophore “points”?
RDKit represents each pharmacophore feature (donor, acceptor, aromatic, etc.) as a point in 3D space, located at the feature center. These points capture the essential interaction motifs of a ligand without requiring the full atomic detail.
Continue readingHow reliable are affinity datasets in practice?
The Data Bottleneck in AI-Powered Drug Discovery
The pharmaceutical industry is undergoing a profound transformation, driven by the promise of Artificial Intelligence (AI) and Machine Learning (ML). These technologies offer the potential to escape the industry’s persistent challenges of high costs, protracted development timelines, and staggering failure rates. From accelerating the identification of novel biological targets to optimizing the properties of lead compounds, AI is poised to enhance the precision and efficiency of drug discovery at nearly every stage
Yet, this revolutionary potential is constrained by a fundamental dependency. The power of modern AI, particularly the deep learning (DL) models that excel at complex pattern recognition, is directly proportional to the volume, diversity, and quality of the data they are trained on. This creates a critical bottleneck: the high-quality experimental data required to train these models—specifically, the protein-ligand binding affinity values that quantify the strength of an interaction—are notoriously scarce, expensive to generate, and often of inconsistent quality or locked within proprietary databases.
Continue readingChatGPT can now use RDKit!
All chemistry LLM enthusiasts were treated to a pleasant surprise on Friday when Greg Brockman tweeted that ChatGPT now has access to RDKit. I’ve spent a few hours playing with the updated models and I have summarized some of my findings in this blog.
Featurisation is Key: One Version Change that Halved DiffDock’s Performance
1. Introduction
Molecular docking with graph neural networks works by representing the molecules as featurized graphs. In DiffDock, each ligand becomes a graph of atoms (nodes) and bonds (edges), with features assigned to every atom using chemical properties such as atom type, implicit valence and formal charge.
We recently discovered that a change in RDKit versions significantly reduces performance on the PoseBusters benchmark, due to changes in the “implicit valence” feauture. This post walks through:
- How DiffDock featurises ligands
- What happened when we upgraded RDKit 2022.03.3 → 2025.03.1
- Why training with zero-only features and testing on non-zero features is so bad
TL:DR: Use the dependencies listed in the environment.yml file, especially in the case of DiffDock, or your performance could half!
Continue readingNarrowing the gap between machine learning scoring functions and free energy perturbation using augmented data
I’m delighted to report our collaboration (Ísak Valsson, Matthew Warren, Aniket Magarkar, Phil Biggin, & Charlotte Deane), on “Narrowing the gap between machine learning scoring functions and free energy perturbation using augmented data”, has been published in Nature’s Communications Chemistry (https://doi.org/10.1038/s42004-025-01428-y).
During his MSc dissertation project in the Department of Statistics, University of Oxford, OPIG member Ísak Valsson developed an attention-based GNN to predict protein-ligand binding affinity called “AEV-PLIG”. It featurizes a ligand’s atoms using Atomic Environment Vectors to describe the Protein-Ligand Interactions found in a 3D protein-ligand complex. AEV-PLIG is free and open source (BSD 3-Clause), available from GitHub at https://github.com/oxpig/AEV-PLIG, and forked at https://github.com/bigginlab/AEV-PLIG.
Estimating the Generalisability of Machine Learning Models in Drug Discovery
Machine learning (ML) has significantly advanced key computational tasks in drug discovery, including virtual screening, binding affinity prediction, protein-ligand structure prediction (co-folding), and docking. However, the extent to which these models generalise beyond their training data is often overestimated due to shortcomings in benchmarking datasets. Existing benchmarks frequently fail to account for similarities between the training and test sets, leading to inflated performance estimates. This issue is particularly pronounced in tasks where models tend to memorise training examples rather than learning generalisable biophysical principles. The figure below demonstrates two examples of model performance decreasing with increased dissimilarity between training and test data, for co-folding (left) and binding affinity prediction (right).
